Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
André, Fabrice, Prof, O'Regan, Ruth, Prof, Ozguroglu, Mustafa, Prof, Toi, Masakazu, Prof, Xu, Binghe, Prof, Jerusalem, Guy, Prof, Masuda, Norikazu, MD, Wilks, Sharon, MD, Arena, Francis, MD, Isaacs, Claudine, Prof, Yap, Yoon-Sim, MD, Papai, Zsuzsanna, MD, Lang, Istvan, Prof, Armstrong, Anne, MD, Lerzo, Guillermo, MD, White, Michelle, MD, Shen, Kunwei, Prof, Litton, Jennifer, MD, Chen, David, PhD, Zhang, Yufen, PhD, Ali, Shyanne, Taran, Tetiana, MD, Gianni, Luca, Dr
Published in The lancet oncology (01.05.2014)
Published in The lancet oncology (01.05.2014)
Get full text
Journal Article
Web Resource